Navigation Links
Limiting Eligibility for Medical Studies Can Omit Women,,African-Americans, Stanford Study Finds

STANFORD, Calif.--(BUSINESS WIRE)--May 24, 2007 - A new analysis has found that many alcohol treatment studies are designed in ways that inadvertently omit women and African-Americans from participation. The Stanford University School of Medicine researcher who led the effort said the findings should remind all scientists that strict study eligibility criteria can have unintended, negative consequences.

In reviewing data from a pool of 100,000 alcohol treatment patients, Keith Humphreys, PhD, professor of psychiatry and behavioral sciences, determined that women and African-Americans were substantially more likely to be excluded from treatment studies than men or non-African-American patients, because of eligibility requirements involving psychiatric problems, employment and housing problems, and drug use.

"Researchers' own study designs are thwarting their good-faith efforts to recruit representative patient samples," said Humphreys, whose paper will be published in the June issue of Alcoholism: Clinical and Experimental Research. "If we want health-care practice to be guided by research, we're going to have to do a better job at studying patients that clinicians actually see."

Medical studies typically exclude certain patients from participation. While some exclusions are often necessary--to protect patient safety, for example--Humphreys suspects researchers often use exclusions in their studies out of habit or tradition. In other cases, researchers may use eligibility criteria to enroll only "desirable" patients in their study, in an effort to make the trial run smoothly or to increase the chances that a favored treatment will show positive outcomes.

Humphreys said such exclusions could have dangerous implications. "If treatments are tested on, and developed for, only part of the population, that means everyone excluded is at greater risk when they use health care," said Humphreys. For t his reason, the National Institutes of Health has instructed researchers to design their studies to ensure adequate enrollment of all populations, including women and racial minorities.

"The NIH, and we as a society, have decided that the burden and benefits of health research should be shared by everyone," said Humphreys, who is also on the staff of the Veterans Affairs Palo Alto Health Care System. "It's a moral and political stance and we're obligated to live up to it."

For the analysis, Humphreys and his colleagues looked at data sets from five previous alcohol treatment studies that enrolled more than 100,000 patients. They then explored the impact of six exclusion criteria commonly used in treatment outcome research: psychiatric problems, neurological problems, medical problems, drug use, non-compliance issues, and social and residential instability.

The researchers found that women were 62 percent more likely than men to be disqualified from studies that required social and residential stability. Women were 29 percent more likely to be excluded from studies that disqualified patients with psychiatric problems, and 20 percent more likely to be excluded for medical problems.

They also found that African-Americans were 46 percent more likely than non-African-Americans to be excluded from studies that required social and residential stability, and 23 percent more likely to be excluded based on drug-use criteria.

"The end result can be a sample that over-represents Caucasian males relative to the treatment population," the authors noted in their paper.

Humphreys stressed that he doesn't believe his fellow researchers are acting out of prejudice or purposefully excluding patients. "Most researchers want women in the studies, but they don't realize that the way they design the study undermines their intentions," he said. "A researcher may say, 'I don't want anyone who is depressed in my alcohol study,' and not stop to consid er that the majority of depressed people are women."

Based on the paper's findings, Humphreys said he would encourage researchers to carefully examine the rationale of a study's eligibility criteria. "Researchers need to say to themselves, 'I'm only going to make the decision to exclude certain patients if there is a good reason for it,'" he said.

Humphreys and his colleagues are also urging designers of alcohol treatment studies to stop excluding patients with drug problems. "Eighty percent of patients with alcohol problems use some sort of drug, so there is a strong case for including these patients in studies," he said.

This study was funded by the National Institute on Alcohol Abuse and Alcoholism, and the Department of Veterans Affairs Health Services Research and Development Service. Humphreys' co-authors include the VA's Kenneth Weingardt, PhD, and Alex Harris, PhD.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions -- Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.

Contact

Print Media
Michelle Brandt, 650-723-0272
mbrandt@stanford.edu
or
Margarita Gallardo, 650-723-7897
mjgallardo@stanford.edu
or
Broadcast Media
M.A. Malone, 650-723-6912
mamalone@stanford.edu


'"/>




Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
10. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):